Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

zacks.com - 2026-07-09 09:56:07

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-07 13:11:07

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

247wallst.com - 2026-07-07 12:30:17

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-07-07 10:41:13

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

zacks.com - 2026-07-07 09:56:08

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-07-02 10:51:08

It might pull it off, provided several things fall right in place.

fool.com - 2026-07-01 15:45:00

The U.S. ​Food and ‌Drug Administration has ​selected Eli ​Lilly and Regeneron , ⁠among ​seven companies, ​for a pilot program ​to ​accelerate reviews of ‌new ⁠domestic pharmaceutical manufacturing facilities, CNBC ​reported ​on ⁠Monday citing ​an ​FDA ⁠spokesperson.

reuters.com - 2026-06-29 15:03:21

Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.

cnbc.com - 2026-06-29 14:50:03

Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.

fool.com - 2026-06-27 20:00:00

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors

feeds.newsfilecorp.com - 2026-06-26 07:00:00

TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

globenewswire.com - 2026-06-25 16:05:00

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

fool.com - 2026-06-25 09:53:00

Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.

zacks.com - 2026-06-23 15:26:10

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

fool.com - 2026-06-23 02:45:00

AbbVie reportedly set to take over Apogee, Satya Nadella wants to upturn AI, and more

fool.com - 2026-06-22 07:30:00

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing

globenewswire.com - 2026-06-22 07:00:00

There could be additional catalysts for this drugmaker over the next year.

fool.com - 2026-06-17 02:30:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-12 10:41:12

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-11 10:00:00

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron P

gurufocus.com - 2026-06-10 16:00:00

LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.

businesswire.com - 2026-06-10 15:00:00

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-09 13:35:00

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 17:38:30

Regeneron Pharmaceuticals remains a "Buy," driven by EYLEA HD expansion, strong DUPIXENT growth, and promising pipeline assets. EYLEA HD U.S. sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. Recent FDA approvals and pending regulatory decisions for EYLEA HD and CEMDISIRAN provide near-term catalysts and franchise durability.

seekingalpha.com - 2026-06-08 02:48:49

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

zacks.com - 2026-06-04 14:25:14

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-04 10:00:00

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026.

globenewswire.com - 2026-06-04 07:00:00

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-02 16:32:00

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.

zacks.com - 2026-06-01 11:35:11

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-01 11:35:10

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-05-29 12:31:47

Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients

globenewswire.com - 2026-05-28 16:00:00

If you're looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech innovators.

247wallst.com - 2026-05-28 11:04:00

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-05-28 10:00:00

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-05-26 16:53:00

Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

newsfilecorp.com - 2026-05-25 11:31:00

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ: REGN) concerning potential violations of the federal securities laws. In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was "hopeful" for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS" and an "opportunity to have a statistically significant, clinically meaningful benefit on OS.

newsfilecorp.com - 2026-05-25 00:12:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-22 10:41:11

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU).

globenewswire.com - 2026-05-22 07:00:00

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-05-21 18:40:00

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement demonstrated improvement in organ function, despite short follow-up First results from the Phase 1/2 LINKER-AL2 trial to be detailed in an ASCO oral presentation; the Phase 2 portion of the trial with registrational intent is ongoing TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2 trial evaluating Lynozyfic® (linvoseltamab) in adults with second-line-plus systemic amyloid light chain (AL) amyloidosis, which will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting on Friday, May 29 at 2:45 p.m.

globenewswire.com - 2026-05-21 17:01:00

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) lost significant market capitalization on May 16, 2026, when the Company disclosed that its Phase 3 melanoma trial of fianlimab combined with Libtayo failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here.

globenewswire.com - 2026-05-21 09:00:00

Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo i

gurufocus.com - 2026-05-20 10:00:00

NEW YORK--(BUSINESS WIRE)--Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. During the Q1 2026 e.

businesswire.com - 2026-05-20 09:00:00

REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.

zacks.com - 2026-05-19 15:30:54

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

zacks.com - 2026-05-19 12:56:07

Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in. NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab).

prnewswire.com - 2026-05-19 09:00:00

Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%. NEW YORK, May 18, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 disclosure that its Phase 3 melanoma trial of fianlimab + Libtayo failed to meet its primary endpoint versus Keytruda.

prnewswire.com - 2026-05-18 18:24:00

Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal late-stage clinical trial. The sharp selloff followed Regeneron's announcement that its high-dose fianlimab and cemiplimab combination failed to significantly outperform Merck's Keytruda in a Phase 3 study involving patients with previously untreated metastatic melanoma.

invezz.com - 2026-05-18 15:25:19